PDCD1 and pachyonychia congenita: In addition, using the KP2 orthotopic PC mouse model, triple therapy with the CXCR1/2 inhibitor SX-682, FOLFIRINOX, and checkpoint inhibition (anti-PD-1/anti-CTLA-4) resulted in significantly increased survival compared with other groups [97].